Endocannabinoid Oxygenation by Cyclooxygenases, Lipoxygenases, and Cytochromes P450: Cross-Talk between the Eicosanoid and Endocannabinoid Signaling Pathways by Rouzer, Carol A. & Marnett, Lawrence J.
Published: September 19, 2011
r2011 American Chemical Society 5899 dx.doi.org/10.1021/cr2002799|Chem. Rev. 2011, 111, 5899–5921
REVIEW
pubs.acs.org/CR
Endocannabinoid Oxygenation by Cyclooxygenases, Lipoxygenases,
and Cytochromes P450: Cross-Talk between the Eicosanoid and
Endocannabinoid Signaling Pathways
Carol A. Rouzer and Lawrence J. Marnett*
A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Departments of Biochemistry, Chemistry, and Pharmacology,
Vanderbilt Institute of Chemical Biology, Center in Molecular Toxicology, Vanderbilt Ingram Comprehensive Cancer Center,
Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, United States
CONTENTS
1. Introduction 5899
1.1. Eicosanoid Biosynthetic Pathways 5899
1.2. Endocannabinoid Biosynthetic Pathways 5899
2. Oxygenation of Endocannabinoids and Related
Compounds by Eicosanoid Pathway Enzymes 5901
2.1. Lipoxygenases: Studies with Puriﬁed or Partially
Puriﬁed Proteins 5901
2.2. Cyclooxygenases: Studies with Puriﬁed or Par-
tially Puriﬁed Proteins 5903
2.3. Cytochromes P450: Studies with Puriﬁed or
Partially Puriﬁed Proteins 5907
2.4. Oxygenation of Endocannabinoids in Intact
Cells and in Vivo 5908
2.5. Metabolic Fate of PG-Gs and PG-EAs 5910
3. Cross-Talk between the Endocannabinoid and Eico-
sanoid Signaling Pathways 5911
3.1. Endocannabinoids as a Source of Free Acid
Eicosanoids 5911
3.2. Oxygenated Endocannabinoids as Receptor
Ligands 5912
3.2.1. Activity at Known Receptors 5912
3.2.2. Activity at Novel Receptors 5914
3.3. Oxygenation as a Termination of Endocanna-
binoid Signaling 5915
3.4. Substrate-Selective COX-2 Inhibition 5916
4. Future Challenges 5917
Author Information 5917
Biographies 5918
Acknowledgment 5918
Abbreviations 5918
References 5919
1. INTRODUCTION
The discovery of the cannabinoid receptors CB1 and CB2 in
1988
1,2 and 1990,
3 respectively, and of the endogenous canna-
binoid ligands (endocannabinoids) arachidonoylethanolamide
(AEA) and 2-arachidonoylglycerol (2-AG) in 1992
4 and 1995,
5
respectively, represented major strides in the understanding of
cannabinoid physiology and pharmacology. The realization that
both endocannabinoids are derivatives of arachidonic acid (AA)
also revealed a potential interrelationship between the endocan-
nabinoid and eicosanoid signaling systems that is just beginning
to be unraveled. In this review, we explore what is known about
the interplay between the two lipid signaling networks and discuss
thechallengesandopportunitiesoﬀeredbythisnewﬁeldofinquiry.
1.1. Eicosanoid Biosynthetic Pathways
AAisanω-6tetraunsaturatedfattyacidthatisacomponentof
mammalian cell membrane phospholipids, where it is predomi-
nantly esteriﬁed at the sn-2 position. AA’s role in eicosanoid
signaling was ﬁrst discovered in 1964, when Van Dorp et al. and
Bergstr€ om et al. showed that incubation of the radiolabeled fatty
acid with bull seminal vesicles led to the formation of prosta-
glandin E2 (PGE2).
6,7 Since that time, we have come to appreci-
ate that a wide range of stimuli (depending on cell type, tissue
context, and physiologic state) can trigger the activation of
cytosolic phospholipase A2 (cPLA2) and/or other phospholi-
pases, leading to the release of free AA from phospholipid pools.
The free fatty acid is then subject to oxidative metabolism by
cyclooxygenase 1 and/or 2 (COX-1 and/or COX-2), leading to
the formation of the endoperoxide PGH2. Tissue-speciﬁc meta-
bolism of PGH2 by a group of PG synthases yields the biologi-
callyactivePGs(PGE2,PGD 2,PGF2α),prostacyclin(PGI2),and
thromboxane A2 (TxA2) (Figure 1a).
8,9 Alternatively, free AA
may be metabolized by one of a variety of lipoxygenases (LOXs)
that catalyze regio- and stereospeciﬁc oxygenation, yielding hydro-
peroxyeicosatetraenoic acids (HPETEs). These compounds are
enzymatically or chemically reduced to the corresponding hydroxy-
eicosatetraenoic acids (HETEs) or undergo further metabolism.
Multiple lipoxygenations produce the lipoxins,
10 or in the case of
5-HPETE, epoxidation followed by hydrolysis or glutathione adduc-
tion yields the leukotrienes (LTs)
9,11 (Figure 1b). Finally, free AA
may be oxidized at each of its double bonds or at the ω-terminus by
cytochromes P450, leading to the epoxyeicosatrienoic acids (EETs)
or HETEs
12 (Figure 1c). Members of each of these classes of com-
pounds possess a unique range of biological activities.
1.2. Endocannabinoid Biosynthetic Pathways
Endocannabinoids are also synthesized from AA-containing
phospholipids, but by very diﬀerent pathways. Activation of
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phospholipase C (PLC) leads to hydrolysis of phosphatidylinositol
4,5-bisphosphate(PIP2),producingdiacylglycerol(DAG).Because
PIP2 is enriched in AA at the sn-2 position in most cells, and most
PLCs favor substrates containing AA, a large proportion of the
DAGformedinthisreactionalsocontainsAA.HydrolysisbyDAG
lipases produces 2-AG (Figure 2a).
1315 2-AG can theoretically
also be formed from the hydrolysis of DAGs produced in other
reactions, such as the sequential hydrolysis of phosphatidylcholine
Figure 1. (a) Cyclooxygenase pathway of AA metabolism. AA is converted to PGG2 at the cyclooxygenase active site of COX-1 or COX-2 and is then
reducedtoPGH2attheperoxidaseactivesite.PGH2spontaneouslydecomposestoyieldPGE2orPGD2,butthesecompounds,aswellasPGF2α,PGI2,
andTxA2,arealsoproducedenzymaticallybyspeciﬁcsynthases.PGI2andTXA2areunstableandspontaneouslydecomposetoyield6-keto-PGF1αand
TXB2, respectively. The ethanolamide and glyceryl ester of PGH2 produced from the metabolism of AEA and 2-AG, respectively, are converted to the
samerangeofeicosanoidproductsasPGH2withtheexceptionoftheTXA2analogue.(b)LipoxygenasepathwayofAAmetabolism.AAisconvertedby
LOXenzymes to position-speciﬁcHPETEs, whichare then reducedto thecorresponding HETEs. 5-LOXalso converts 5-HPETEto LTA4, whichmay
then be metabolized to LTB4or LTC4. The glutathionyl moiety of LTC4is subject to enzymatic hydrolysis, yielding LTD4and LTE4. The actions of multiple
LOXenzymesleadtotheformationoflipoxins.AnexampleisprovidedforthesynthesisoflipoxinA4throughmultiplestepscatalyzedby5-LOXandeither15-
LOX or 12-LOX. (c) Cytochromes P450 catalyze the epoxygenation of AA at each of the double bonds, producing the range of products shown.5901 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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(PC) by phospholipase D (PLD) and phosphatidic acid phospha-
tase. However, the importance of such alternative pathways in
endocannabinoid lipid signaling is unclear.
Once generated, 2-AG is subject to hydrolysis, primarily by
monoacylglycerol (MAG) lipases. The serine lipases αβ-
hydrolase domains 6 and 12 (ABHD6 and ABHD12) have also
been shown to play a role in 2-AG catabolism. On the basis of
expression level and relative activity, MAG lipase, ABHD12, and
ABHD6 are estimated to account for 85%, 9%, and 4% of 2-AG
hydrolysis in mouse brain, respectively.
16,17 Fatty acid amide
hydrolase (FAAH), the enzyme primarily responsible for the
hydrolysis of AEA, can also hydrolyze 2-AG; however, it plays
onlyaminorrolephysiologically(approximately1%inmouse
brain).
16,18 Under some circumstances, nonspeciﬁc esterases
may catalyze 2-AG hydrolysis. For example, human carboxy-
lesterases 1 and 2 (CES1 and CES2) metabolize 2-AG as
eﬃciently as human and rat MAG lipase. Expression of CES1
accounts for 55% of 2-AG hydrolysis in the THP1 human
monocytic leukemia cell line, suggesting that this may be a
primarycatabolicrouteinsomeleukocytes.
19Thepresenceof
CES1 isoforms in rodent plasma could contribute to rapid
2-AG hydrolysis in those species; however, CES enzymes are
not found in human plasma.
20,21
It is generally agreed that the primary route to AEA begins
with N-arachidonoylphosphatidylethanolamine (NAPE), which
is synthesized by the transfer of AA from the sn-1 position of
a donor phospholipid to phosphatidylethanolamine (PE) by a
Ca
2+-dependent N-acyltransferase (NAT). Hydrolysis of this
precursor by an N-acylphosphatidylethanolamine-hydrolyzing
PLD (NAPE-PLD) yields AEA
13,14,2226 (Figure 2b). Because
NAT transfers a range of fatty acids from the sn-1 position of the
donor phospholipid, NAPE biosynthesis is not speciﬁc for the
incorporation of AA. Thus, this pathway produces a spectrum of
fattyacylethanolamides,leadingtoaquestionofAEAspeciﬁcity.
Relevant to this question is the ﬁnding of Leung et al. that alter-
native pathways for the synthesis of AEA exist in mice bearing a
targetedmutationoftheknowngeneforNAPE-PLD.
27Asnoted
above, the major route of degradation of AEA and similar fatty
acyl amides is hydrolysis by FAAH.
18
Traditionally, the eicosanoid and endocannabinoid signaling
systems have been investigated independently of one another,
anditisconceivablethatendocannabinoidsignalingoccursinthe
absence of eicosanoid pathway activation and vice versa. How-
ever, the lipases that initiate both sets of pathways are responsive
to some of the same second messengers (e.g., elevations in
intracellularCa
2+).Therefore,itislikelythat,incellscarryingthe
enzymatic machinery for both pathways, they will be activated
together, presenting the potential for biochemical and pharma-
cologic cross-talk. As will be discussed below, the complexity of
possible pathway interactions is increased by the fact that some
enzymesoftheeicosanoidbiosyntheticpathwayscan metabolize
endocannabinoidsaswellasAA.Theseconsiderations,combined
with the sharing of common precursor lipid pools, guarantee
multiple sites of interconnection. In this review, we will focus
primarily on interactions that occur at the site of enzymatic
reactions and receptor activation as outlined in the literature over
thepast20years.Aconsiderableliteraturealsoexistsontheeﬀects
of endocannabinoids on the expression of genes in the eicosanoid
biosynthetic pathways and the converse. This topic will not be
dealt with here.
2. OXYGENATION OF ENDOCANNABINOIDS AND RE-
LATED COMPOUNDS BY EICOSANOID PATHWAY
ENZYMES
Although the primary fate of endocannabinoids is inactivation
throughhydrolysis,increasingevidenceindicatesthatthesecom-
pounds are also subject to most of the oxidative metabolic path-
ways that lead to eicosanoid biosynthesis. Here we outline the
speciﬁc enzymatic reactions shared by endocannabinoids and
AA, compare their eﬃciency as substrates, and catalog the pro-
ducts formed.
2.1. Lipoxygenases: Studies with Purified or Partially Pur-
ified Proteins
LOXscatalyzetheabstractionofahydrogenatomfromabisal-
lylic carbon of a polyunsaturated fatty acid, followed by double
bond migration and oxygen addition. The result is conversion of
Figure 2. (a) Biosynthetic pathway for 2-AG. PIP2 containing AA at
the sn-2 position is hydrolyzed by PLC to yield DAG and IP3. DAG is
then further hydrolyzed by MAG lipase to 2-AG. (b) Biosynthetic
pathway for AEA. An arachidonoyl moiety is transferred from the sn-1
position of a phospholipid, in this case PC, to the amino group of PE by
NAT.TheresultingproductNAPEisthenhydrolyzedbyNAPE-PLDto
yield AEA and PA.5902 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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a 1,4-cis,cis-diene structure of the polyunsaturated fatty acid to a
1,3-cis,trans-5-peroxyl radical, which is reduced sequentially to a
hydroperoxide and then the corresponding alcohol
28 (Figure 3).
Most lipoxygenases will accept multiple fatty acids as substrates,
but exhibit a high degree of regioselectivity and stereospeciﬁcity
regarding the site and orientation of oxygen addition. The
enzymes that metabolize AA are usually named by designating
the number of the carbon atom where oxygen addition occurs.
For most mammalian LOX enzymes, the antarafacial stereo-
chemistry of oxygen addition leads to the formation of the (S)-
hydroperoxide.
29
Although the majority of LOX enzymes display a preference
for free fatty acid substrates, precedent exists for oxygenation of
phospholipid-bound fatty acids and cholesteryl esters in the case
of the rabbit reticulocyte 15-LOX, the human leukocyte 15-LOX-1,
and the soybean 15-LOX-1.
3032 Thus, the possibility that ester
oramidederivativesofAAcouldserveasLOXsubstrateswasnot
unreasonable,andHampsonetal.andUedaetal.weretheﬁrstto
test this hypothesis.
33,34 Hampson et al. demonstrated metabo-
lism of AEA by the 12-LOX enzymatic activity in an ammonium
sulfate fractionof ratpinealgland.Theyidentiﬁedtheproduct of
the reaction as the ethanolamide of 12-HETE (12-HETE-EA)
following reduction of the hydroperoxide with NaBH4. This
result indicated that the 12-LOX exhibited the same regioselec-
tivity for AEA as it did for AA (Figure 4). Measurement of the
totalamountofproductsynthesizedfromAAandAEAsuggested
that the pineal gland 12-LOX metabolized the two substrates
with equal eﬃciency. Hampson et al. went on to show that the
puriﬁed 12-LOX from porcine leukocytes also catalyzed oxyge-
nation of AEA to yield 12-HETE-EA and that the 15-LOX from
soybeans produced predominantly 15-HETE-EA and minor
amounts of 11-HETE-EA from AEA. In the case of the porcine
12-LOX, full kinetic studies yielded values for Km and Vmax that
were statistically identical for AEA and AA, suggesting that the
enzyme did not diﬀerentiate between the two substrates. In
similar studies, Ueda et al. reported that the 12-LOX from
porcine leukocytes, the 15-LOX-1 from rabbit reticulocytes,
and the 15-LOX from soybeans could oxygenate AEA at rates
roughlycomparabletothoseforAA.Incontrast,humanplatelet
12-LOX was only marginally active, and porcine leukocyte
5-LOXwasinactivewithAEAasthesubstrate.AsforHampson
et al., characterization of the reaction products by Ueda et al.
showed that the active enzymes exhibited the same regioselec-
tivity for AEA as was observed for AA, producing the com-
parable ethanolamide product. Further characterization of the
products of the porcine leukocyte 12-LOX and the soybean
15-LOXalsoconﬁrmedthatthestereospeciﬁcityofthereaction
with AEA was identical to that of AA, with the major reduced
products identiﬁed as 12(S)-HETE-EA and 15(S)-HETE-EA,
respectively.
Van der Stelt et al. carried out a structureactivity study,
evaluating the capacity of the soybean 15-LOX to oxygenate
linoleic acid and its amide, methylamide, dimethylamide, and
ethanolamide derivatives.
35 The soybean enzyme oxygenated
free linoleic acid at carbon 13, and the same regioselectivity was
observedforallamides.KineticstudiesrevealedsimilarKmvalues
for the free acid, amide, and ethanolamide. Vmax values were
similarfor the free acid andethanolamide, while thevaluefor the
amide was approximately 50% lower. Kinetic constants were not
reported for the methylamide and dimethylamide. Zadelhoﬀ
et al. conﬁrmed the ability of the soybean 15-LOX to eﬃciently
metabolizeAEAtothe15(S)-hydroperoxyproduct (Figure4).
36
They also demonstrated that the 5-LOX enzymes from tomato
and barley could metabolize AEA with eﬃciency equal to and
better than, respectively, that of AA. However, these enzymes
exhibited diﬀerent regioselectivities for the two substrates,
producing 11-HETE-EA, after reduction, from AEA in contrast
to 5-HETE from AA.
Moody et al. extended the study of endocannabinoid lipox-
ygenation by demonstrating that the 12-LOX from porcine
leukocytes, but not the enzyme from human platelets, could
eﬃcientlyoxygenate2-AG.
37Thereducedreactionproductfrom
the leukocyte enzyme was the glycerol ester of 12(S)-HETE
(12(S)-HETE-G),indicatingthattheenzymeexhibitedthesame
regio- and stereoselectivity with 2-AG as with AA (Figure 4).
Kinetic studies with the porcine leukocyte 12-LOX revealed that
the eﬃciency of 2-AG metabolism was approximately 40% as
high as that of AA (as determined by kcat/Km), and a structure
activity relationship evaluation ranked a series of arachidonoyl
estersas substrates from highest tolowest eﬃciencyas 2-glyceryl
ester (2-AG) > 1-glyceryl ester (1-AG) > hydroxyethyl ester >
methoxyethyl ester > ethyl ester. This work was expanded by
Kozak et al., who showed that soybean 15-LOX, rabbit reticulo-
cyte 15-LOX-1, human 15-LOX-1, and human 15-LOX-2 all
metabolized 2-AG eﬃciently, whereas potato and human leuko-
cyte 5-LOXs showed no activity with this substrate.
38 Kinetic
studies revealed that both human 15-LOX enzymes oxygenated
2-AG with eﬃciency equal or superior to that of AA, and
structureactivity proﬁles for the soybean 15-LOX, rabbit
reticulocyte 15-LOX-1, and human 15-LOX-2 were all similar
Figure 3. Mechanism of the lipoxygenase reaction. A hydrogen atom is abstracted from the bisallylic carbon of a polyunsaturated fatty acid, yielding a
1,5-pentadienyl radical. Addition of oxygen at the terminus of this radical yields a peroxyl radical, which is then reduced to the hydroperoxide.5903 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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to those observed for the porcine leukocyte 12-LOX as reported
by Moody et al.
37
The lipoamino acids are a class of compounds related to the
endocannabinoidsinthattheyarefattyacylamidesthatmayplay
a role in nociception and inﬂammation. Prusakiewicz et al.
showed that the human platelet 12-LOX, porcine leukocyte
12-LOX, rabbit reticulocyte 15-LOX-1, and human 15-LOX-2
all metabolized the lipoamino acids N-arachidonoylglycine
(NAGly), N-arachidonoylalanine (NAla), and N-arachido-
noyl-γ-aminobutyric acid (NAGABA).
39 Following reduction,
theproductsformedwerethecorrespondingaminoacidamides
of 12- and 15-HETE, corresponding primarily to the regio-
selectivityofeachenzymeforAA.Eﬃcienciesoflipoaminoacid
oxygenation based on kcat/Km values were between 42% and
105% of those of AA. This was the ﬁrst report that the human
platelet 12-LOX could metabolize a nonfree fatty acid sub-
strate; however, the investigators noted that this enzyme
displayed some loss of regioselectivity, as the amino acid amide
derivatives of both 12-HETE and 15-HETE were produced
(Figure4).Prusakiewicz etal. also showed thatreticulocyte15-
LOX-1metabolizedthevanilloidreceptorligandsN-arachidon-
oyldopamine (NADA) and N-arachidonoylvanillylamide
(arvanil, NAVA) at 2327% the rate of AA, while O-(3-methyl)-
N-arachidonoyldopamine (OMDA) was not a substrate.
39
All of the vanilloids were poor substrates for the other LOX
enzymes.
As noted above, the primary route of degradation of AEA is
hydrolysis catalyzed by FAAH.
18 Saghatelian et al. have demonstrated
that mice bearing a targeted deletion of the gene for FAAH exhibit an
increasenotonlyinfattyacylethanolamides,butalsoinN-acyltaurines,
a previously unknown class of fatty acyl amides.
40 These compounds
had no endocannabinoid activity, but were shown to activate multiple
membersofthetransientreceptorpotentialfamilyofcalciumchannels.
Turman et al. have reported that, like 2-AG and AEA, N-arachidon-
oyltaurine (N-AT) is oxygenated by the human 15-LOX-2 and
porcine leukocyte 12-LOX.
41 As in the case of the lipoamino acids,
N-AT was also an eﬃcient substrate for the human platelet 12-LOX.
The human 15-LOX-2 and leukocyte 12-LOX exhibited the same
regioselectivity for N-AT as for AA, but the platelet 12-LOX again
showed some loss of regioselectivity, producing the taurine amides of
both 12-HETE and 15-HETE (Figure 4).
In addition to AEA, the ethanolamides of other fatty acids have
been detected in various tissues. The identiﬁcation of docosahexae-
noylethanolamide (DHEA) in the brain led Yang et al. to explore the
lipoxygenase-dependent oxygenation of this endocannabinoid-related
molecule.
42,43 Incubation of human polymorphonuclear leukocytes
(PMNs) or mouse brain homogenates with DHEA led to the forma-
tion of a number of oxygenated metabolites, including 17-hydroxy-
DHEA, 10,17-, 14,17-, and 7,17-dihydroxy-DHEA, and (15-hydroxy-
16(17)epoxydocosapentaenoyl)ethanolamide (15-HEDPEA). The
production of 17-hydroxy-DHEA by incubation of DHEA with the
15-LOX from soybeans conﬁrmed the LOX-dependent formation
of this molecule. Furthermore, the presence of naturally occurring
17-hydroxy-DHEA in mouse brain homogenates suggests the possi-
bilitythatlipoxygenationofDHEAmayhavephysiologicalrelevance.
43
2.2. Cyclooxygenases: Studies with Purified or Partially
Purified Proteins
The two COX isoforms catalyze the bisdioxygenation of AA,
yielding the hydroperoxy endoperoxide PGG2 and the subse-
quent reduction of the hydroperoxide group of PGG2 to form
PGH2 (Figure 5). The two enzymes exhibit 60% sequence iden-
tityandnearlyoverlappingthree-dimensionalstructures.Invitro,
their kinetics with AA as the substrate are very similar. Thus,
research aimed at understanding the functional diﬀerences be-
tweenthetwoisoformshasfocusedprimarilyontheirdiﬀerential
Figure 4. Products ofthe action oflipoxygenases on endocannabinoids
and related AA-derived compounds. The general reactions of 12-LOX
and 15-LOX are shown, along with the structures of the endocannabi-
noid analogues that have been tested as substrates. The identities of the
majorproductsareindicated,alongwiththesourcesoftheenzymesthat
have been shown to catalyze the reaction. Note that, in the case of the
human platelet 12-LOX metabolizing arachidonoyl amino acids, both
12- and 15-hydroxylated products were identiﬁed. For this reason, 12-
LOX is shown (in parentheses) as catalyzing the formation of this
positional isomer.5904 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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expression. In most tissues, the gene for COX-1 is constitutively
expressed, whereas COX-2 expression is inducible by stimuli
such as growth factors, tumor promoters, and inﬂammatory
agents. For this reason, it is generally believed that COX-1
produces PGs that regulate homeostatic functions, whereas
COX-2 is responsible for PG formation in pathological states
suchasinﬂammationandtumorigenesis.BothCOXisoformsare
inhibited by nonsteroidal anti-inﬂammatory drugs (NSAIDs),
such asaspirin, ibuprofen, andindomethacin, and this isbelieved
to be the primary mechanism of action of these widely used
pharmaceuticals. The association of COX-2 with the inﬂamma-
tory response led to the development of COX-2-selective
inhibitors (coxibs), with the expectation that such compounds
would retain the anti-inﬂammatory activity of traditional NSAIDs,
but with reduced side eﬀects (e.g., gastrointestinal toxicity).
Clinical experience with the coxibs that have reached the
market (celecoxib, rofecoxib, valdecoxib) has supported this
expectation; however, the recently discovered cardiovascular
toxicity of these drugs has demonstrated that the relative roles
of the two COX isoforms are not as clearly demarcated as was
originally thought.
4447
COX-1, the ﬁrst of the two isoforms to be discovered, has a
strongrequirementforafreecarboxylgroupinthesubstrate.
48,49
Following the discovery of the endocannabinoids, Yu et al.
challenged the assumption that this requirement also applies to
COX-2.
48 Their discovery that puriﬁed COX-2, but not COX-1,
could oxygenate AEA was the ﬁrst demonstration of a substrate-
based functional diﬀerence between the two isoforms. They
showedthat the product of the reaction of COX-2 withAEA was
the ethanolamide of PGE2 (PGE2-EA) (Figure 6), but the
eﬃciency of oxygenation of AEA was only about 18% as high
as that of AA, on the basis of kcat/Km determinations. The major
contributor to this diﬀerence in substrate preference was an
approximately 4-fold higher Km for AEA as compared to AA. So
et al. exploited this ﬁnding in their studies of the dynamics of
catalysis and inhibition of the two COX isoforms.
50 They
conﬁrmed the results of Yu et al. and used AEA as a model
substrate to explore the requirement of each enzyme for a free
carboxyl group in the substrate.
Kozak et al. performed structureactivity studies to explore
the basis for AEA oxygenation using ovine COX-1 and murine
COX-2.
51For COX-2,themaximalrate ofAEAoxygenationwas
27% that of AA. For COX-1, this value was 11%, indicating that
AEA is a preferredsubstrate for COX-2, but that COX-1 also has
some capacity to oxygenate this substrate. Elimination of the
terminal hydroxyl group of the ethanolamide moiety of AEA
resulted in a marked reduction of oxygenation by both enzymes.
Addition of a 1(S)-methyl group to the ethanolamide moiety
of AEA increased catalytic activity approximately 2.4-fold for
COX-2, but 3.6-fold for COX-1, reducing the COX-2:COX-1
selectivity ratio to 1.6:1 from 2.5:1 for AEA. In contrast, a
1(R)-methyl substituent increased the rate of COX-2 oxygena-
tion by 1.2-fold, but decreased the rate for COX-1 by 75%,
resulting in an increase in COX-2 selectivity to 12:1. The latter
compound is (R)-methandamide, a metabolically stable AEA
analoguethatisfrequentlyusedinstudiesofAEApharmacology.
Dimethyl substitution at the 1-position of the ethanolamide
resulted in activity similar to that of AEA for COX-2, but a
30% reduction in activity for COX-1 compared to that of AEA.
Stereoselectiveeﬀectswerealsoobservedwithsubstitutionatthe
2-position of the ethanolamide, but the diﬀerences between the
two COX isoforms were not as profound as those observed with
1-substitution. In most cases, replacement of the hydroxyl group
of an analogue with a methoxy group decreased, but did not
eliminate, oxygenation eﬃciency.
51
Kozak et al. extended the study of COX-dependent endocan-
nabinoid oxygenation to include 2-AG.
49 They showed that COX-2
metabolizes 2-AG with kcat and Km values similar to those of AA,
while COX-1 utilizes this substrate poorly. The products of the
reaction using puriﬁed COX-2 were the glyceryl esters of PGE2,
PGD2,1 1 - H E T E ,1 5 - H E T E ,a n d1 2 - h y d r o x y h e p t a d e c a t r i e n o i ca c i d
Figure 5. Mechanism of the cyclooxygenase reaction. The 13-pro-(S)-
hydrogen of AA is removed by a radical at Y385 of the COX active site.
The resulting radical migrates to position 11, which serves as the site of
oxygen addition. Following the formation of the endoperoxide between
carbons 11 and 9, a single bond links carbons 8 and 12 to form the
prostanoid ﬁve-membered ring. The radical then migrates to carbon 15,
whichbecomesthesiteofthesecondoxygenaddition,formingaperoxyl
radical, whichisthenreducedtoahydroperoxide(PGG2).Reductionof
the 15-hydroperoxide using electrons from a coreductant (Ared) at the
peroxidase active site yields PGH2.5905 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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(HHT) (Figure6).Therelativequantitiesofthesemetaboliteswere
not signiﬁcantly diﬀerent from those of the comparable free acid
compounds formed when COX-2 metabolized AA. (Note that
PGH2 spontaneously decomposes to form PGE2,P G D 2,a n d
HHT. 11- and 15-HETE are formed by monoxygenation of AA
without cyclization.
44)S t r u c t u r e activity studies of various arachi-
donoyl esters revealed that 2-AG was utilized most eﬃciently
followed by 1-AG and the hydroxyethyl ester. Esters that lack a free
hydroxyl group were not substrates for COX-2, nor was cholesteryl
ester or AA-containing DAG.
Prusakiewicz et al. demonstrated that substrate selectivity
between the two COX isoforms is not restricted to 2-AG and
AEA.
52 They reported that COX-2 but not COX-1 metabolizes
the lipoamino acid NAGly with an eﬃciency approximately 10%
that of AA and 23% that of 2-AG, but 8-fold higher than that of
AEA, on the basis of kcat/Km values. The reaction yielded the
glycine amides of products comparable to those obtained with
AA (Figure 6). Expansion of these studies showed that COX-2
could also oxygenate NAla and NAGABA at 2040% the
maximal rate of AA, although the products of the reaction were
notidentiﬁed.
39Thesearethe ﬁrstexamplesofchargedsubstrates
that are selective for COX-2. Neither COX isoform oxygenated
N-AT or the vanilloids NADA, OMDA, or arvanil.
39,41
Recent crystal structures of murine COX-2 in complex with
AA
53 or 1-AG
54 provide insight into the structural determinants
of AA and 2-AG oxygenation. (Note that, under aqueous
conditions, 2-AG undergoes rapid base-catalyzed acyl migration
to form an equilibrium mixture of 1-AG and 2-AG at a ratio of
approximately 8:2 (section 2.4).
55 Thus, use of 2-AG for crystal-
lization studies is impractical.) Like COX-1, COX-2 is a homo-
dimer, with each monomer consisting of an epidermal growth
factor domain near the dimer interface, a membrane-binding
domain, through which the enzyme interacts with one leaﬂet of
the lipid bilayer, and a large catalytic domain. The active site of
eachmonomerconsistsofalarge“lobby”regionthatisboundby
the four orthogonal α-helices of the membrane-binding domain.
The roof of the lobby is demarcated by a “constriction site”
formedbyarginine-120,tyrosine-355,andglutamate-524.Above
the constriction is a hydrophobic L-shaped channel that extends
deep into the protein and forms the enzyme active site (Figure 7).
InthemuCOX-2:AA(mu=murine)structure,theorientationof
substratebindinginthischannelisdistinctlydiﬀerentforthetwo
monomers (Figure 8). In monomer B, AA is bound productively
with its ω tail at the top of the channel and its carboxyl group
forming a single hydrogen bond with tyrosine-355 at the con-
strictionsite.Thecyclooxygenasereactionisinitiatedbyaradical
on tyrosine-385, which is located at the bend of the L-shaped
channel (Figures 7 and 8). The binding orientation of AA in the
active site places the tyrosyl radical in proximity to AA’s 13-pro-
(S)-hydrogen, which is abstracted in the ﬁrst step of the reaction
Figure6. Productsoftheactionofcyclooxygenaseonendocannabinoidsandrelatedcompounds.COX-2producesPGH2astheprimaryproduct,plus
11-and15-HETEasminorproducts.Intheabsenceofanyadditionalmetabolizingenzymes,PGH2decomposestoformPGD2,PGE2,andHHT.Some
or all of these compounds have been identiﬁed as products of the metabolism of endocannabinoid-like compounds as indicated above. For NAGly, a
HETE-Glyderivative(s)wasdetected,buttheexactposition(s)ofthehydroxylgroup(s)wasnotdetermined.Endocannabinoidmetabolism(2-AGand
AEA) has been demonstrated for human COX-2; however, recombinant murine COX-2 has been used in the majority of these studies.5906 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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mechanism (Figures 5 and 8). In monomer A, AA is bound
unproductively in a reverse orientation with its carboxylate
forming hydrogen bonds with tyrosine-385 and serine-530 at
thebendoftheactivesitechannel.Movementofthesidechainof
leucine-531 provides room for AA’s ω tail to lie above arginine-
120 at the constriction site (Figure 8).
53
ThemuCOX-2:1AGstructureagainrevealssubstratebindingina
productive conformation in monomer B and an unproductive
conformation in monomer A; however, the diﬀerences in the two
conformationsaremoresubtlethanthoseseeninthemuCOX-2:AA
structure (Figure 9). As for AA, the productive conformation of
1-AG in the active site of monomer B places the ω tail deep in the
hydrophobic channel with tyrosine-385 oriented close to the 13-
pro-(S)-hydrogen of 1-AG. Movement of the side chain of leucine-
531providesroomforthe2,3-dihydroxypropylmoietyof1-AGabove
the side chain of arginine-120. The only hydrophilic interaction
Figure 7. (A) Domain structure of the COX enzymes. The N-terminus (not visible in the crystal structure) connects to the epidermal growth factor
(EGF) domain. The EGF domain, in turn, connects to the membrane-binding domain, which comprises four α-helices (AD). Helix D connects the
membrane-binding domain to the large catalytic domain. α-helices are shown in blue, β-sheets are shown in green, and the heme prosthetic group is
shown in red. (B) Drawing of the COX structure highlighting the hydrophobic channel of the cyclooxygenase active site. The large lobby region, which
opensintothemembrane-bindingdomain,isseparatedfromtheL-shapedchannelabovebyaconstriction.KeycatalyticresiduesTyr-385,Arg-120,and
Ser-530areshowningreen.Thehemeprostheticgroupisinred.ThesestructuralcharacteristicsshownhereforovineCOX-1arerepresentativeofboth
isoforms. Panel B kindly provided by M. Garavito. Both ﬁgures reprinted from ref 44. Copyright 2003 American Chemical Society.
Figure 8. Comparison of the conformations of AA in the active sites of the two monomers of murine COX-2. The left frame displays AA bound in
monomer A of the COX-2 homodimer. It is bound in an inverted catalytically unproductive conformation in which its carboxyl group is H-bonded to
Tyr-385 and Ser-530. The ω end of the fatty acid lies across Arg-120 and abuts Leu-531. Two molecules of AA are modeled in monomer A because of
ambiguities in modeling from the electron density map. The right frame displays AA bound in monomer B of the homodimer in a productive
conformation.ThecarboxylateisH-bondedtoArg-120,andthefattyacidchainprojectsupintotheactivesite.Theωendofthefattyacidprojectsintoanalcove
above Ser-530, and the 13-pro-(S) hydrogen is located adjacent to the hydroxyl group of Tyr-385, which is converted to a tyrosyl radical during turnover.5907 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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between the substrate and the enzyme is a hydrogen bond
between the phenolic hydroxyl of tyrosine-355 and the carboxyl
oxygenof1-AG.InmonomerA,1-AGisorientedasinmonomerB,
but the ω tail is not inserted deeply enough into the hydro-
phobic channel to bring the 13-pro-(S)-hydrogen into close proxi-
mity of tyrosine-385 (Figure 9). Hence, this conformation is
unproductive.
54
In COX-1 an ionic interaction between the carboxylate of AA
and arginine-120 is a key determinant of substrate binding. The
absence of this interaction, conﬁrmed by the muCOX-2:AA
crystal structure, helps to explain COX-2’s ability to metabolize
neutralesterandamide derivatives,whicharepoor substrates for
COX-1.Thedataalsosuggest thattheﬂexibility ofleucine-531is
an important structural feature of COX-2 that allows it to
accommodate the 2,3-dihydroxypropyl group of 1-AG; however,
mutation of this residue to alanine, phenylalanine, or proline had
minimal eﬀect on the eﬃciency of oxygenation of AA, 1-AG, or
2-AG. For both AA and 1-AG, the only hydrophilic interaction
withtheenzymewasahydrogenbondtotyrosine-355.Mutation
of this residue to phenylalanine reduced the catalytic eﬃciency
for metabolism of AA by approximately 80% (as determined by
kcat/Km),whileitincreasedtheeﬃciencyformetabolismof2-AG
by approximately 3-fold. The latter result was explained on the
basis of elimination of hydrogen bonds between tyrosine-355
and other constriction site residues, giving 2-AG greater ﬂex-
ibility to attain an optimal binding position.
54
A highly conserved diﬀerence between the COX isoforms is
thepresenceofvaline-523,arginine-513,andvaline-434inCOX-
2, as opposed to isoleucine-523, histidine-513, and isoleucine-
434 in COX-1. The smaller side chains in COX-2 form a cavity,
calledthe “side pocket”, which increases the volumeof the active
site.Thesidepockethasbeenexploitedasabindingsiteformany
highly eﬀective COX-2-selective inhibitors. It is notable that the
side pocket did not serve as a binding site for 1-AG in the
muCOX-2:1AG structure, and mutation of arginine-513 to
histidine had no eﬀect on AA or 1-AG binding as observed in
respectivecocrystalstructuresobtainedwiththemutantenzyme.
TheR513Hmutationalsohadnoeﬀectontheeﬃciencyof1-AG
or 2-AG oxygenation (as determined by kcat/Km) in these
studies.
54 Prior site-directed mutagenesis studies had suggested an
important role for both the constriction site residues and the side
pocket in the oxygenation of 2-AG, AEA, and lipoamino acids by
COX-2.
49,51,52,56Thus,theneartotalabsenceofinteractionbetween
1-AG and these active site residues as observed in the crystal
structure was unexpected. However, both sets of studies agree that
the overall binding orientation and reaction mechanism for en-
docannabinoid oxygenation are the same as for AA oxygenation.
2.3. Cytochromes P450: Studies with Purified or Partially
Purified Proteins
Cytochromes P450 are heme-containing monooxygenases
that catalyze the NADPH-dependent biotransformation of a
majority of clinically used drugs and xenobiotic toxicants as well
as many endogenous substrates. There are 57 human P450
enzymes that display a wide range of substrate speciﬁcity, tissue
distribution,andphysiologicalfunction.P450enzymes,primarily
of the 2C and 2J families, catalyze the epoxygenation of AA at all
fourdoublebondpositions,leadingtotheformationof5,6-,8,9-,
11,12-, and 14,15-EETs. P450s, primarily of the 4A and 4F
families, catalyze terminal hydroxylation, leading to the forma-
tion of HETEs (Figure 10).
57
Soon after the discovery of AEA, Bornheim et al. investigated
its P450-mediated metabolism using the enzymatic activity in
mouse tissue microsomes. They observed the formation of
twenty and two metabolites using liver and brain microsomes,
respectively. A combination of enzyme inducers and antibodies
directed against speciﬁc P450s indicated that 3A family enzymes
were primarily responsible for AEA metabolism by liver micro-
somes, but played a lesser role in the brain. These investigators
did not identify the metabolites.
58
More detailed studies of P450-mediated AEA metabolism did
notoccuruntil2007,whenSnideretal.reportedtheformationof
Figure 9. Comparison of the conformations of 1-AG in the active sites of the two monomers of murine COX-2. The left frame displays 1-AG in an
unproductiveconformationinmonomerAofthehomodimer,whereastherightframedisplays1-AGboundinaproductiveconformationinmonomerB
ofthehomodimer.Thetwoconformationsarecomparable,buttheωendsofthefattyacylgroupsdiﬀerinconformationsothatthe13-pro-(S)hydrogen
is only close enough to Tyr-385 in monomer B to enable abstraction during the catalytic cycle.5908 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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theethanolamidesofEETs(EET-EAs)andHETE-EAsfromthe
incubation of AEA with human kidney and liver microsomes.
P450 4F2 was primarily responsible for AEA metabolism by
kidneymicrosomes,andtheonlyproductformedwas20-HETE-
EA. Human liver microsomes produced 5,6-, 8,9-, 11,12-, and
14,15-EET-EAs in addition to 20-HETE-EA. The major P450
responsible for EET-EA formation in liver microsomes was
3A4.
59 Soon thereafter, the same group reported that human
recombinant P450 2D6 does not metabolize AA, but does
convert AEA to 20-HETE-EA and all four EET-EAs. AEA was
a high-aﬃnity substrate for P450 2D6, and this enzyme ac-
counted for most AEA oxygenation in brain mitochondrial
preparations. Further studies demonstrated that a common
genetic polymorphism of human P450 3A4 (I118 V) leads to a
60% reduction in EET-EA formation by this enzyme. One new
monooxygenated and four new dioxygenated metabolites were
formed by the I118V mutant enzyme as compared to products
formed by the wild-type P450 3A4. These results suggest that
P450 polymorphisms may be a source of variability in endocan-
nabinoid metabolism and signaling.
60 Further support for this
hypothesis came from studies of AEA metabolism by wild-type
and polymorphic P450 2B6 and P450 2D6 enzymes.
61 Finally,
the discovery that AEA is a high-aﬃnity substrate for the orphan
P4504X1,withtheprimaryproductidentiﬁedas14,15-EET-EA,
suggests that endocannabinoid metabolism may be an as yet
unexplored function of additional P450 enzymes.
62
Despite the considerable research on P450-mediated AEA
oxygenation, little current evidence exists for direct metabolism
of 2-AG. 2-AG was not a substrate for P450 4X1 and was not
metabolized by microsomes from the livers and kidneys of rats,
even following pretreatment by salt-loading or phenobarbital,
which induces the expression of some P450s. Similarly, incuba-
tion of 2-AG with recombinant P450 2C8, 2C11, or 2C3, known
AA epoxygenases, did not lead to product formation.
62,63
2.4.OxygenationofEndocannabinoidsinIntactCellsandin
Vivo
The capacity of some eicosanoid biosynthetic enzymes to
metabolize endocannabinoids in vitro does not automatically
imply that these reactions are of physiologic signiﬁcance. Thus,
investigators have explored this potential new biosynthetic path-
way in intact cells and organisms. The ﬁrst reported study of this
naturewasbyEdgemondetal.,whoshowedthathumanplatelets
convert exogenous AEA to 12(S)-HETE-EA and that human
PMNs convert AEA to 15(S)-HETE-EA and to a lesser extent
12(S)-HETE-EA.
64 These results were generally consistent with
those conducted in cell-free systems, although it is noteworthy
that the ﬁnding with human platelets would not have been
predicted from the poor eﬃciency of AEA oxygenation by the
puriﬁed platelet 12-LOX in vitro (section 2.1).
34 Further studies
of lipoxygenation of endocannabinoids in intact cells were
reported by Moody et al. and Kozak et al., who showed that
Figure 10. Examples of P450-catalyzed oxygenations of AA or AEA. Reactions shown are those that have been identiﬁed for AEA as well as AA.
Additional reactions for AA have been reported.5909 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
Chemical Reviews REVIEW
COS-7 cells transfected with porcine leukocyte 12-LOX or
human 15-LOX-1 or 15-LOX-2 produced 12(S)-HETE-G or
15-HETE-G, respectively, from exogenous 2-AG.
37,38 Kozak
et al. also demonstrated conversion of 2-AG to 15-HETE-G by
human keratinocytes, which constitutively express 15-LOX-2.
Turmanetal.incubatedmurineresidentperitonealmacrophages
(RPMs)withN-ATandidentiﬁed12-HETE-Talongwithminor
amounts of 15-HETE-T as reaction products.
41
TreatmentofthemurineRAW264.7macrophage-likecellline
with bacterial lipopolysaccharide (LPS) and interferon-γ (IFN-γ)
induces expression of COX-2. Kozak et al. showed that cells
pretreated in this way synthesize the glyceryl ester of PGD2
(PGD2-G)fromexogenous2-AGandPGD2-EAfromexogenous
AEA.
49,51PGD2-Gformationwasalsodetectedinthemediumof
LPS- and INF-γ-pretreated RAW264.7 cells exposed to iono-
mycin, which stimulates release of endogenous 2-AG. The
ﬁnding that LPS/IFN-γ pretreatment was required and that
synthesis was blocked by an isoform-selective COX-2 inhibitor
veriﬁedthatPGD2-G formation byRAW264.7 cells was COX-2-
dependent in these experiments.
PGD2 is themajorPG produced by RAW264.7cells from AA.
Therefore, the production of PGD2-G and PGD2-EA as the only
COX-2-derived endocannabinoid products suggested that the
PGD synthase in RAW264.7 cells is capable of eﬃciently
metabolizing PGH2-G or PGH2-EA. PGH2 spontaneously de-
composes to form PGD2 and PGE2 in ratios varying from 1:3 to
1:5, and PGH2-G and -EA suﬀer the same fate. Thus, in the
absenceofenzymaticconversionoftheendoperoxideintermedi-
ates, one would expect to detect both PGE2 and PGD2 glyceryl
ester or ethanolamide upon incubation of RAW264.7 cells with
2-AG or AEA, respectively, with PGE2 derivatives predominat-
ing. The preponderance of PGD2 derivatives suggests that
PGH2-G and PGH2-EA are substrates for PGD syntheases. This
discovery led Kozak et al. to explore the capacity of other PG
synthases to metabolize PGH2-G and PGH2-EA.
51 They con-
ﬁrmed that puriﬁed hematopoietic PGD synthase, in the pre-
sence of COX-2, produced PGD2-G from 2-AG with an
eﬃciency of about 50% compared to that of the conversion of
AA to PGD2. Incubation of HCA-7 cells with 2-AG resulted in
the formation of PGE2-G and PGF2α-G, while incubation with
AEA resulted in the corresponding ethanolamides. These results
suggestedthatthePGEandPGFsynthasesbothacceptPGH2-G
and PGH2-EA as substrates, a conclusion that was conﬁrmed for
PGE synthase through incubation of the recombinant micro-
somal enzyme (mPGE synthase 1) with 2-AG in the presence of
COX-2. PGE2-G was formed with eﬃciency approximately
6075% of that of conversion of AA to PGE2. Similarly the
reduction of PGD2-EA to PGF2α-EA by puriﬁed PGF synthase
conﬁrmed this enzyme’s ability to accept ethanolamide
substrates.
65 Prostacyclin synthase in human platelet micro-
somes converted 2-AG and AEA to PGI2-G and PGI2-EA,
respectively, in the presence of COX-2. The eﬃciency of PGI2-
G and PGI2-EA synthesis was 7080% of that of PGI2 synthesis
from AA. Only human recombinant TX synthase showed poor
ability to metabolize PGH2-G and PGH2-EA to the correspond-
ing TXA2 analogues. Its ability to produce TXB2-G (the stable
hydrolysis product of TXA2-G) from 2-AG in the presence of
COX-2 was only 5% as high as the eﬃciency of TXB2 formation
from AA.
51 Together, the results suggest that COX-2-dependent
endocannabinoid oxygenation has the potential to produce a
range of ﬁnal products nearly as diverse as the products formed
from AA oxygenation. The data also suggest that, with the
exception of TX, the spectrum of products formed from 2-AG
orAEAwillbesimilartothatformedfromAAinanygivencellor
tissue.
The studies discussed above clearly demonstrate that COX-2-
and LOX-dependent endocannabinoidoxygenation can occur in
the intracellular environment. However, most of these experi-
ments were carried out with exogenous 2-AG or AEA, leaving
unanswered the question of a cell’s ability to execute these
biosyntheticpathwaysusingsubstratesderivedfromendogenous
lipid stores. To address this concern, Rouzer and Marnett
investigated the biosynthesis of PG-Gs by murine RPMs in
response to a zymosan stimulus.
66 Cells pretreated with LPS to
induce COX-2 expression then exposed to a maximal zymosan
stimulus synthesized approximately 16 pmol/10
7 cells of PG-Gs
compared to 21000 pmol/10
7 cells of PGs. The primary PG-Gs
produced, PGE2-G and 6-ketoPGF1α-G (the stable breakdown
product of PGI2-G), were consistent with the identity of the
major PGs produced by these cells. Levels of free AA released in
response to zymosan were approximately 10-fold higher than
thoseof2-AG,whichpartiallyaccountedforthelargediﬀerential
in PG versus PG-G synthesis. However, even in the presence of
1 μM exogenous 2-AG, PGs were synthesized at higher levels
(820 pmol/10
7 cells) than PG-Gs (78 pmol/10
7cells). Incuba-
tionofRPMswithexogenousPGE2-Gindicatedthatthecompound
was stable, so degradation did not account for the comparatively
low yield of PG-Gs in these cells. In contrast, exogenous 2-AG
was rapidly hydrolyzed to AA, which accounted for PG synthesis
upon addition of this substrate.
Murine RPMs constitutively express high levels of COX-1, so
LPS-pretreated cells contain both isoforms of the enzyme.
Rouzer and Marnett showed that selective inhibition of COX-2
bySC236inthesecellsreducedzymosan-stimulatedPGproduc-
tion by 17% and PG-G production by 49%.
66 This result
suggested that the majority of PG formation and a substantial
quantity of PG-G formation by the cells were COX-1-depen-
dent. In contrast, when LPS-pretreated RPMs were exposed to
exogenous 2-AG, SC236 reduced PG and PG-G synthesis by
76% and 88%, indicating a predominant role for COX-2 under
these conditions. The apparent involvement of COX-1 in
zymosan-stimulatedPG-Gsynthesiswasfurtherexploredusing
RPMs from mice bearing targeted deletions of the genes for
COX-1 or COX-2.
67 These results conﬁrmed a major role for
COX-1 in zymosan-dependent PG and PG-G formation as
indicated by the ﬁnding that COX-1 knockout markedly
reduced the synthesis of both classes of product, whereas the
eﬀect of COX-2 knockout was not statistically signiﬁcant.
Knockout of either enzyme substantially reduced the synthesis
of both PGs and PG-Gs from exogenous 2-AG. A somewhat
diﬀerentapproachwastakenbyYuetal.,whoreplacedthegene
f o rC O X - 2w i t ht h eg e n ef o rC O X - 1 ,g e n e r a t i n gaC O X - 1>
COX-2 “knockin” mouse.
68 They found that LPS-pretreated
RPMs from these mice produced lower quantities of PG-Gs
from exogenous 2-AG than RPMs from wild-type mice, again
supportingapredominantroleforCOX-2inthecaseofexogenously
provided endocannabinoid. The substantial role for COX-1, parti-
cularly in zymosan-stimulated PG-G synthesis, was unexpected
considering the fact that 2-AG is a relatively poor substrate for this
enzyme. Kinetics studies suggested the possibility that COX-2 is
rapidly inactivated in zymosan-stimulated cells. If this is true, it
w o u l da l s oh e l pt oe x p l a i nt h el o wl e v e lo fP G - Gs y n t h e s i si n
response to zymosan, since COX-1-dependent oxygenation of
2-AG would be expected to be ineﬃcient.5910 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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Attempts to detect oxygenation products of endocannabi-
noids in vivo have met with some success. Weber et al. detected
low levels of PGE2-EA and PGD2-EA in the lungs and kidneys of
wild-type mice following intravenous injection of AEA.
69 Higher
levels of these compounds, in addition to PGF2α-EA, were
detected in the lungs, kidneys, livers, and small intestines of
mice bearing a targeted deletion of the gene for FAAH, but only
after AEA injection. In these mice, knockout of FAAH reduced
hydrolysis of AEA, providing higher levels of this substrate for
oxygenation by COX-2. These results conﬁrm that PG-EAs can
beformed invivo,buttheconditionsrequired fortheirdetection
in this study were not physiological.
Hu et al. provided convincing evidence of the presence of
PGE2-Ginhomogenatesofthehindpawsofrats.
70Quantitiesof
PGE2-G detected were low (∼190 fmol/paw) compared to
those of PGE2 (∼140 pmol/paw) and 2-AG (∼800 pmol/paw),
and levels were undetectableinthebrain and spinalcord. Higher
quantities of PGE2-G were detected in the paws from rats
pretreated with MAG lipase inhibitors, which prevented 2-AG
breakdown, thus providing higher levels of substrate for PGE2-G
formation. Lower levels of PGE2-G were detected in the paws of
animals treated with COX inhibitors. However, no change in
PGE2-Glevelsresultedfromcarageenaninjection,whichinduces
an inﬂammatory response in the paw accompanied by increased
expressionofCOX-2.Itshouldbenotedthatcarefulcomparison
of the published mass spectrum of the PGE2-G isolated from rat
paw to that of the standard suggests the presence in the paw
sample of a second compound of 2 units higher mass-to-charge
ratio. It is quite possible that the material isolated from the paw
was actually a mixture of PGE2-G and PGF2α-G, which would
likely not have separated under the conditions used for chroma-
tography in that study.
Although detection of PG-Gs in vivo has proved challenging,
Chen et al. reported readily measurable quantities of the glyceryl
esters of P450-derived EETs, including 2-(11,12-epoxyeicsatrie-
noyl)glycerol (2-11,12-EET-G) and 2-(14,15-epoxyeicosatrie-
noyl)glycerol (2-14,15-EET-G), in lipid extracts from rat spleen
and kidney. 2-11,12-EET-G alone was found in the brain.
71
Quantities of the epoxygenase metabolites ranged from 0.2 to
1.5 ng/g of tissue as compared to those of 2-AG, which ranged
from5to11ng/goftissue.Therefore,thesemetabolitesappearto
be present in much higher quantity in vivo than PG-Gs. This
discoveryisnotableinthattheseglycerylepoxygenasemetabolites
are the only oxygenated endocannabinoids that were discovered
in vivo prior to being generated enzymatically in vitro. However,
the failure to demonstrate direct P450-dependent 2-AG epoxy-
genation (section 2.2) leaves the origin of these species unclear.
2.5. Metabolic Fate of PG-Gs and PG-EAs
To understand the production of oxygenated endocannabi-
noids detected in vivo requires knowledge of the chemical and
metabolic fate of these compounds. 2-AG is initially formed
containingAAinthesn-2positionofglycerolasaresultofthefact
that most AA in the parent phospholipid pool is esteriﬁed at this
location.However, inaqueous solution, thearachidonoylmoiety
of 2-AG undergoes acyl migration to the sn-1 position, yielding
an equilibrium mixture of 1-AG and 2-AG at a ratio of roughly
8:2.Thisbase-catalyzedﬁrst-orderreactionoccurswithahalf-life
of approximately 10 min at 37 C and pH 7.4 in the absence of
serum and 2.3 min in the presence of 10% serum.
55 Thus, it is
unclear whether the substrate encountered by COX-2 in vivo is
most likely to be 2-AG or 1-AG, although as noted above
(section 2.2), both isomers are recognized by the enzyme.
Similarly, PG-Gs and HETE-Gs synthesized from 2-AG are
subject to acyl migration, so that these compounds might be
present as either the 1- or 2-glyceryl esters in vivo.
Although2-AGandPG-Gsaresubjecttoacylmigration,these
compounds and the fatty acyl ethanolamides are highly stable to
chemical hydrolysis under physiological conditions. Thus,
Kozak et al. explored their metabolic fate.
72 When injected
intravenouslyintorats,PGE2-Gdisappearedfromthecirculation
within5min,whilePGE2-EAexhibitedaplasmahalf-lifeofover
6 min and a large volume of distribution. Consistent with these
ﬁndings, PG-Gs were rapidly hydrolyzed in rat plasma with a
half-life of 14 s ex vivo, whereas PG-EAs were stable.
In contrast, PG-Gs were much more stable in human plasma
andwholeblood(half-livesof>10and7min,respectively),and
no hydrolysis was observed in canine, bovine, or human
cerebrospinal ﬂuid. PG-EAs were stable to hydrolysis in all of
these biological ﬂuids.
Human 15-hydroxyprostaglandin dehydrogenase, theenzyme
primarily responsible for inactivation of PGs, oxidized PGE2-G
andPGE2-EAlesseﬃcientlythanPGE2.Productsofthereaction
indicated that PGE2-G was oxidized only at carbon 15. The
enzyme was nearly inactive with PGF2α-G. Together, the results
suggest that PG-EAs are relatively stable metabolically to enzy-
matic hydrolysis and oxidation. Thus, failure to detect these
compounds invivois notlikely due torapid oxidationto 15-keto
derivatives. In contrast, PG-Gs are subject to rapid hydrolysis,
especially in frequently used rodent models, a conclusion also
supportedbyHuetal.,whoobservedrapidhydrolysisofPGE2-G
uponinjectionintoratpaw.
70Theproductof PG-Ghydrolysisis
the corresponding PG. Thus, failure to detect these compounds
in vivo may be due to rapid conversion to PGs, which are
indistinguishable from PGs formed directly from AA.
The rapid hydrolysis of PG-Gs in vivo led investigators to
explore the enzymes that might catalyze this reaction. Potential
candidates include FAAH and MAG lipase, the enzymes primar-
ily responsible for hydrolysis of AEA and 2-AG, respectively.
However, Ross et al. showed that FAAH inhibitors had no eﬀect
onthebindingofPGE2-EAtovariousmembranepreparations.
73
Similarly, Fowler and Tiger showed that PGD2-G, PGE2-G, and
PGF2α-GdidnotblockthehydrolysisofAEAor2-oleoylglycerol
by cytosolic and membrane fractions from rat brain homo-
genates,
74 and Matias et al. showed that PGD2-EA, PGE2-EA,
andPGF2α-EAdidnotblockAEAhydrolyticactivityinN18TG2
cellmembranes,whicharerichinFAAH.
75Theseresultssuggest
that PG-Gs and PG-EAs do not interact with FAAH or MAG
lipase. This conclusion was further supported by Vila et al., who
showed that PG-Gs are poor substrates for puriﬁed FAAH and
MAG lipase and that speciﬁc inhibitors of these enzymes only
partially blocked the hydrolysis of PGE2-G in RAW264.7 cells
and dog brain homogenates.
76
The discovery that human CES1 and CES2 can eﬃciently
metabolize both PGE2-Gand PGF2α-G, but notthe correspond-
ing ethanolamides, provides some insight into the mechanism of
PG-G catabolism. CES1 was responsible for 80% and 97% of
PGE2-G and PGF2α-G hydrolysis, respectively, in cultured hu-
man THP-1 monocytic leukemia cells.
19 The presence of CES
enzymes in rodent, but not human, plasma could explain the
striking species diﬀerences in PG-G half-lives in these body
ﬂuids.
20,21,72 Thus, it appears likely that rapid hydrolysis of PG-
GsiscatalyzedbyanenzymedistinctfromFAAHorMAGlipase,
but the identity of the enzyme is unknown.5911 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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Biologically active free acid EETs are inactivated by epoxide
hydrolases, which catalyze hydrolysis to the corresponding
dihydroxy metabolites. Similarly, 5,6-EET-EA was subject to
epoxide hydrolase-mediated hydrolysis, while exhibiting resis-
tance to hydrolysis of the amide bond by FAAH. Resistance to
FAAH rendered 5,6-EET-EA more stable in mouse brain homo-
genates than AEA.
77
3. CROSS-TALK BETWEEN THE ENDOCANNABINOID
AND EICOSANOID SIGNALING PATHWAYS
The common role of AA and the ﬁnding of oxygenation of
endocannabinoids by some eicosanoid biosynthetic enzymes
suggest a number of possible ways in which cross-talk between
theendocannabinoidandeicosanoidpathwaysmayoccur.These
include (1) hydrolysis of endocannabinoids to provide AA for
eicosanoid biosynthesis, (2) production of oxygenated endocan-
nabinods that are later hydrolyzed and act at eicosanoid recep-
tors, (3) production of oxygenated endocannabinoids that act at
eicosanoid or endocannabinoid receptors, (4) production of
oxygenated endocannabinoids that act at distinct receptors,
and (5) termination of endocannabinoid signaling by oxygena-
tion of 2-AG or AEA. These possibilities have been explored to
varying degrees, and results suggest that at least some of the
potentialcross-talkscenariosdo,infact,occurincellsandinvivo,
whereas others are unlikely. Details of these investigations
and the challenges that have arisen in these studies are out-
lined below.
3.1. Endocannabinoids as a Source of Free Acid Eicosanoids
As noted above, 2-AG or AEA, produced from endogenous
stores or provided exogenously, is subject to hydrolysis, yielding
free AA, which may then be oxygenated by any eicosanoid
biosynthetic enzymes that are present in the cell. This yields
the corresponding free acid product (example for COX-depen-
dent metabolism provided in Figure 11, pathway A). Alterna-
tively, 2-AG or AEA could be oxygenated ﬁrst, in which case the
product eicosanoid glyceryl ester or ethanolamide is also subject
to hydrolysis to produce the free acid eicosanoid (Figure 11,
pathway B). The free acid eicosanoids produced by either
pathway are indistinguishable from each other and from eicosa-
noids formed from AA that is released directly by PLA2-depen-
dent pathways. This complicates the interpretation of data from
experiments involving endocannabinoids in which free acid
eicosanoid levels are measured or their pharmacologic eﬀects
are observed.
A number of approaches help to distinguish the source of free
acid eicosanoids in the complex cellular environment. Inhibitors
of FAAH or MAG lipase block endocannabinoid hydrolysis, but
not the hydrolysis of PG-Gs or PG-EAs. Thus, these inhibitors
lower the level of eicosanoids formed from hydrolysis of en-
docannabinoidsfollowedbyoxygenation(Figure11pathwayA),
but not those formed by oxygenation followed by hydrolysis
(Figure11,pathwayB).MAGlipaseandFAAHinhibitorsshould
alsohaveno eﬀect oneicosanoidssynthesizedfromAAprovided
directly by PLA2-dependent phospholipid hydrolysis. When
exogenous substrates are provided, the use of nonhydrolyzable
endocannabinoid analogues, such as (R)-methandamide and
2-arachidonoyl glyceryl ether (noladin ether) in place of AEA
and 2-AG, respectively, will prevent the formation of free acid
eicosanoids by pathway A and will yield nonhydrolyzable eico-
sanoid amide or ester analogues by pathway B. COX and LOX
inhibitors are frequently used to conﬁrm the enzymatic origin of
an oxygenated metabolite and may help to distinguish between
free acid eicosanoids generated by pathway A versus pathway B.
For example, nonselective COX inhibitors should block prosta-
noid synthesis occurring through either pathway, whereas a
COX-2-selective inhibitor should completely block pathway B
Figure 11. Hydrolyticmetabolismof2-AGandPG-Gs.PathwayA:2-AGmaybehydrolyzed toAA,whichisthen subjectto oxygenationby COX-2or
COX-1,yieldingfreeacidPGs(illustratedherebyPGE2).PathwayB:Oxygenationof2-AGwillproducePG-Gs(illustratedherebyPGE2-G),hydrolysis
of which will yield the corresponding free acid PG. The origin of the free acid PG product, through oxygenation of AA or 2-AG, cannot readily be
distinguished.5912 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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while having a variable eﬀect on pathway A, depending on the
isoforms involved. (However, see section 2.4 above regarding
COX-1-dependent PG-G synthesis in RPMs.) Finally, when
pharmacologic eﬀects are being monitored, cannabinoid and
prostanoid receptor antagonists help to distinguish between the
pharmacologic activities of the parent endocannabinoid and its
possible eicosanoid metabolites.
A substantial number of studies have used exogenously
supplied AEA or 2-AG to investigate the pharmacology of these
compounds.Insomecases,explorationusinginhibitors,receptor
antagonists, and/or nonhydrolyzable endocannabinoid ana-
logues has revealed that the observed physiological responses
were likely due to hydrolysis of the endocannabinoid followed
by COX- or LOX-dependent oxygenation of the resultant AA. A
number of these studies focused on cardiovascular responses to
endocannabinoids, such as contraction or relaxation of isolated
vascular ring preparations
78,79 and changes in arterial pressure in
perfused lung.
80 However, such disparateresponses as inhibition
of prostate carcinoma cell invasiveness and cytotoxicity toward
squamous cell carcinoma cultures have also been reported to be
eicosanoid-mediated.
81,82 These studies concluded that endo-
cannabinoid hydrolysis produced AA for eicosanoid biosyn-
thesis and identiﬁed the eicosanoid species likely responsible for
the observed eﬀect. However, a number of other studies have
suggested eicosanoid-mediated eﬀects of endocannabinoids
without fully identifying the active species. Among the activities
reported are relaxation of bovine arterial rings,
83 cerebral vaso-
dilation in the rabbit,
84 induction of emesis in the shrew,
85
promotion of adipocyte diﬀerentiation,
86 inhibition of IL-2
secretion in splenocytes,
87 inhibition of 5-hydroxytryptamine
receptor-induced head twitch in the mouse,
88 and non-CB
receptor-dependent responses in a battery of cannabinoid res-
ponsiveness tests in mice.
89 Finally, some experiments have
suggested that endocannabinoids can stimulate the release of
AA from phospholipid stores, leading to eicosanoid synthesis
that does not depend on endocannabinoid hydrolysis.
9092
Althoughthemajorityofthesestudiesconcludedthatfreeacid
eicosanoids were formed by endocannabinoid hydrolysis fol-
lowed by oxygenation of the resultant free AA, the possibility of
endocannabinoid oxygenation followed by hydrolysis of the
glyceryl ester or ethanolamide product remained a viable option
in some cases.
82,88 As noted above, PG-EAs and PG-Gs are
resistant to degradation by 15-hydroxyprostaglandin dehydro-
genase when compared to their free acid counterparts. Thus, it is
conceivable that these compounds could serve as a more
metabolically stable pool of PGs that is transported to distant
sitespriortohydrolysisandreceptorbinding. Atpresent, thereis
relatively little direct evidence to support this as a signiﬁcant PG
signaling pathway.
Despite clear demonstrations that some endocannabinoid
pharmacology is really eicosanoid pharmacology resulting from
hydrolysis followed by oxygenation, there are alsomany compel-
ling studies in which exogenously provided endocannabinoids
act intact at CB receptors with no involvement of oxygenase
enzymes.Excellentexamplesareseeninstudiesoftheneurologic
eﬀects of endocannabinoids and in their modulation of mem-
brane transporters. A major role of cannabinoids in the nervous
system is seen in the phenomena of depolarization-induced
suppressions of inhibition (DSI) and excitation (DSE), which
occur in the hippocampus and cerebellum. These regions of the
brain contain large neurons that are regulated by smaller
inhibitory GABAergic or excitatory glutaminergic interneurons.
Electrical or neuronal stimulation resulting in depolarization of
the large neuron stimulates release of endocannabinoids, which
traveltothesmallerinterneuronandsuppressitsactivitythrough
CB1-mediated signaling. Both DSI
93 and DSE
94 in hippocampal
neurons were found to be due to the direct action of endocan-
nabinoids without the inﬂuence of oxygenated metabolites.
Similarly, inhibition of dopamine transport,
95 inhibition of
Ca
2+ eﬄux from T-tubule membranes,
96 stimulation of glucose
uptake,
97 inhibition of endothelin 1-mediated Ca
2+ mobiliza-
tion,
98 and contraction of colonic smooth muscle
99 are not
dependent on the activity of oxygenases. Finally, in contrast to
the numerous studies showing that vascular eﬀects of endocan-
nabinoids were eicosanoid-mediated (see above), Gardiner et al.
showed no eﬀect of COX inhibition on the hemodynamic
response of conscious rats to AEA.
100
These studies vary tremendously with regard to how exten-
sively the potential cross-talk between endocannabinoid and
eicosanoid signaling was explored. In some cases, the simple
inclusion of a COX inhibitor was used to show that an observed
eﬀect was not eicosanoid-mediated. In other cases, multiple
inhibitors and receptor blockers were used, and the ﬁnal
eicosanoid product mediating an eﬀect was identiﬁed. Thus, it
is likely that further reﬁnements of some of these observations
will be made in the future. It is also important to note that the
ﬁndingthatexogenousendocannabinoidscanserveasasourceof
eicosanoids does not necessarily mean that endogenously gen-
erated endocannabinoids are an important source of eicosanoids
in vivo. The addition of exogenous endocannabinoids to cell
culture media or a tissue bath provides a large absolute quantity
of compound that can be hydrolyzed to free AA.
67 Such
quantities of endocannabinoids are not available from endogen-
ous sources. In fact, the levels of endocannabinoids produced in
stimulated cells are usually at least an order of magnitude lower
thanthequantityoffreeAAreleasedforeicosanoidbiosynthesis.
The majority of evidence suggests that the primary source of AA
for stimulus-dependent eicosanoid biosynthesis in most cells/
tissues is provided by PLA2-mediated phospholipid hydrolysis.
However, in vivo studies in mice have shown that blockade of
MAG lipase activity by organophosphorous nerve agents, a
speciﬁcinhibitor(JZL184),orgeneknockoutresultsinincreased
2-AG and decreased AA levels in brain tissue.
101103 Similarly,
mice bearing a targeted deletion of the gene for DAG lipase-α
exhibit decreased brain levels of both 2-AG and AA when
compared to wild-type controls.
104 These results suggest that
2-AG is a source of steady-state AA in mouse brain. In addition,
theﬁndingofsubstantial PGbiosynthesis inzymosan-stimulated
macrophages from cPLA2
/ mice suggests the possibility that
endogenously generated AEA or 2-AG could serve as a source of
AA for stimulus-dependent eicosanoid synthesis under some
circumstances.
67
3.2. Oxygenated Endocannabinoids as Receptor Ligands
3.2.1. Activity at Known Receptors. Definitive studies
have shown that COX-derived oxygenated endocannabinoids
arenotligandsforthetraditionaleicosanoidorendocannabinoid
receptors. Pinto et al. showed that the ethanolamides of PGE2,
PGA2, PGB1, and PGB2 do not bind to the CB1 receptor, and
Ross et al. showed that PGE2-EA’s affinity for the four EP
receptors was at least 2 orders of magnitude lower than that of
PGE2.
73,105 Similarly, Nirodi et al. reported that the binding
affinity of PGE2-G was at least 2 orders of magnitude lower than
thatof PGE2 at allfour EP receptorsand that the compound was5913 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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completely inactive at the FP, DP, TP, and IP receptors.
106 An
analogue of PGF2α-EA, bimatoprost (Figure 12A), is used
clinically for the treatment of glaucoma. Hence, there is an
extensive literature on the pharmacology of PGF2α-EA, indicat-
ing that it does not interact with the FP receptor.
75,107 Consider-
ing the fact that oxygenated endocannabinoids are usually
present at much lower levels than free acid eicosanoids in vivo,
it is highly unlikely that these compounds can successfully
compete for binding to the traditional prostanoid receptors.
Thus, there is no current evidence that PG-Gs or PG-EAs act as
endocannabinoids or free acid prostanoids or that they serve as
antagonistsforthesecompoundsthroughdirectreceptorinterac-
tions.
In contrast, Edgemond et al. and Van der Stelt et al. showed
that the 12(S)-, 12(R)-, and 20-HETE-EAs have nearly the same
aﬃnity for the CB1 receptor as AEA.
64,108 12(S)- and 20-HETE-
EA were also comparable in aﬃnity to AEA in binding to CB2.
15(S)-HETE-EA exhibited poor aﬃnity for both receptors.
Similarly, the l5-LOX product of linoleoyl amide and linoleoyl-
EA demonstrated no aﬃnity for CB1.
109 These results were
Figure 12. (A) Structures of PGF2α-EA and bimatoprost. (B) Structures of compounds tested for the ability to mobilize Ca
2+ in RAW264.7 cells and
H1819 cells.
115 Note that, in aqueous solution, PG-Gs rapidly equilibrate to form a mixture of the 1- and 2-glyceryl esters, with the 1-glyceryl ester
predominatingataratioofapproximately8:2.Incontrast,thestereochemistryofthecorrespondingamideanaloguesremainsﬁxed.EC50valuesaregiven
for Ca
2+ mobilization in H1819 cells. NR indicates no response.5914 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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supported by Hampson et al.,
33 who showed that 12-HETE-EA
was more active than 15-HETE-EA in eliciting cannabinoid-
dependent contraction of mouse vas deferens and in blocking
forskolin-mediated cAMP production. In contrast, Ueda et al.
34
found higher activity for 15-HETE-EA than for 12-HETE-EA in
the vas deferens assay. Thus, it appears that at least some LOX-
derivedmetabolites of AEA have the potential to act as endo-
cannabinoids.
Yangetal.havereportedthattheDHEA-derivedlipoxygenase
metabolites 10,17-dihydroxy-DHEA and 15-HEDPEA have endo-
cannabinoid activity. Both of these compounds showed potency
comparable to that of AEA and superior to that of DHEA at the
CB2 receptor. They were also active at the CB1 receptor, but
required considerably higher concentrations than AEA. In addi-
tion to CB receptor binding, 10,17-dihydroxy-DHEA and
15-HEDPEA inhibited chemotaxis of human PMN, blocked
leukocyteplatelet aggregate formation, and exhibited protec-
tiveactivityinamousemodelofreperfusionsecondorganinjury.
It is unclear, however, whether these eﬀects are mediated by the
activity of these compounds at CB receptors or as yet unidenti-
ﬁed receptors.
43
Snider et al. showed that the P450-dependent metabolite 5,
6-EET-EA has a higher aﬃnity for the CB2 receptor than its
parent AEA. Increased biosynthesis of this compound was
observed concomitantly with augmented CB2 expression in
IFN-γ-stimulated microglia, suggesting that this pathway may
play a role in inﬂammatory signaling in these cells. Chen et al.
showed that the P450 epoxygenase metabolites 2-11,12-EET-G
and 2-14,15-EET-G have aﬃnity for and pharmacologic activity
at CB1 and CB2.
71 These compounds were detected in sizable
quantities in vivo, suggesting that they could play a signiﬁcant
role in endocannabinoid signaling.
Some evidence has been presented that oxygenated eicosa-
noids may act at peroxisome proliferator-activated receptors
(PPARs). Kozak et al. reported that 15-HETE-G, but not
15-HETE,isanagonistatPPAR-αinNIH3T3cellsexpressinga
PPAR-α-dependent luciferase reporter gene.
38 Ghosh et al.
demonstrated that 2-AG activates PPAR-δ in human vascular
endothelial cells by a process that requires COX-2 and prosta-
cyclin synthase.
110 PPAR-δ activation was also observed with
AEA and the nonhydrolyzable analogue of 2-AG, noladin ether,
but not with AA. These results suggest that 2-AG is converted to
PGI2-G, which then serves as a PPAR-δ agonist. However,
6-keto-PGF1α-G, the stable breakdown product of PGI2-G, was
notdetectableinthecells.Similarly,Rockwelletal.demonstrated
that 2-AG, AEA, and noladin ether inhibit IL-2 secretion in
activated Jurkat T cells and primary splenocytes.
111 The eﬀect
was blocked by selective inhibitors of COX-2 and a PPAR-γ
antagonist. The results suggest that the eﬀect was due to a COX-
2-dependent metabolite of 2-AG; however, the ﬁnding that the
same eﬀect could be observed upon addition of AA suggests that
a free acid PG may be the active agent.
87
3.2.2. Activity at Novel Receptors. A number of reports
suggest that PG-Gs and/or PG-EAs have biological activities
distinct from those of their free acid counterparts and may act at
novel receptors. The most extensive studies of this nature have
focused on the biological activity of PGF2α-EA because, as noted
above, an analogue of this compound is used clinically in the
treatment of glaucoma. In the eye, PGF2α-EA and its clinical
counterpart bimatoprost (Figure 12A) have effects similar to those
of PGF2α on ocular tension. However, extensive pharmacologic
data indicate that these compounds do not act at the FP
receptor.
75,107 The discovery of antagonists that block the action
of PGF2α-EA and bimatoprost but not PGF2α in the eye further
supports the conclusion that there are distinct sites of action for
these two compounds.
112,113 Efforts to characterize a specific
PGF2α-EA receptor led Liang et al. to identify six splice variants
of the FP receptor in human ocular tissues.
114 They showed that
HEK293/EBNA cells coexpressing the wild-type FP and the
altFP4 splice variant responded to both PGF2α and PGF2α-EA
bindingwithdistinctpatternsofCa
2+mobilization.Theresponse
to PGF2α-EA but not PGF2α was blocked by antagonists to
bimatoprost. Only PGF2α mobilized Ca
2+ in HEK298/EBNA
cells expressing the wild-type FP receptor alone. The FP
receptor exists as a homodimer. Liang et al. showed that
cells expressing both wild-type FP and altFP4 form hetero-
dimersofthetworeceptorgeneproducts.Theyproposethatit
isthisheterodimericreceptorthatrespondstoPGF2α-EAand
bimatoprost. It will be interesting to see if this paradigm
applies to other biologically active ester and amide derivatives
of prostanoids.
Although not as advanced as the pharmacology of PGF2α-EA,
some progress has been made on characterizing distinct biolo-
gical activities of PG-Gs. Nirodi et al. showed that PGE2-G, but
not PGD2-G, or PGF2α-G induced Ca
2+ mobilization in
RAW264.7 cells.
106 The EC50 for this response was 1 pM, as
compared to 15 nM for PGF2α. Nirodi et al. demonstrated that
no signiﬁcant hydrolysis of PGE2-G occurred within the time
frame of the response, and PGE2 did not elicit Ca
2+ mobilization
in these cells. PGE2-G induced a transient increase in inositol
1,4,5-trisphosphate(IP3)levelsandthemembraneassociationof
protein kinase C(PKC). Anincreaseinlevels of thephosphoryl-
ated forms of the mitogen-activated protein kinases (MAPKs)
and extracellular signal regulated kinases (ERKs) 1 and 2 also
occurred, and this response was attenuated by pharmacologic
blockade of the IP3 receptor and inhibitors of PKC and PLCβ.
TheinvestigatorsconcludedthatPGE2-G,likelythroughbinding
to an as yet unknown receptor, stimulates activation of PLCβ,
leading to IP3 production, Ca
2+ mobilization, PKC activation,
andultimatelyMAPKphosphorylationandactivation.Follow-up
studiesbyRichie-Janettaetal.showedthatthehumannon-small-
cell lung cancer cell line H1819 also responds to PGE2-G with
Ca
2+ mobilization and that the maximal response in these cells
(2.56-fold) was greater than that of RAW264.7 cells (1.53.5-
fold).
115 Structureactivity relationship experiments showed
that the cells responded similarly to PGE2-G and its analogue
PGE2-serinol amide (Figure 12B). PGE2-serinol amide is more
stable to ester hydrolysis than PGE2-G and does not undergo
acyl migration, allowing the investigators to show that both
RAW264.7 cells and H1819 cells responded similarly regardless
of whether the PGE2 moiety was linked at the sn-1 or sn-2
position of the glycerol. In contrast, replacing the ester linkage
with a thioester resulted in a marked reduction in potency. In
these studies, PGF2α-G and its amide analogues were found to
have activity similar to that of PGE2-G. The ethanolamides of
both PGE2 and PGF2α were inactive. These results suggest that
the putative receptor recognizes key features of the glyceryl
headgroup but is not highly speciﬁc for the substituents on the
prostanoid ring.
Asnotedabove(section3.1),inthehippocampus2-AGinvokes
DSI,whichcanbemeasuredelectrophysiologicallyasdecreasesin
miniature inhibitory postsynaptic currents (mIPSCs). Sang et al.
showed that PGE2-G, PGD2-G, PGF2α-G, and PGD2-EA but not
PGE2-EA or PGF2α-EA have an eﬀect opposite that of 2-AG,5915 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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invoking increases in mIPSCs in mouse hippocampal neurons.
116
Since PGE2 and PGD2 had an eﬀect opposite that of their
corresponding esters or amides, and PGF2α had no eﬀect, Sang
et al. concluded that the eﬀects of the glyceryl esters and amides
were not mediated by prostanoid receptors. The eﬀect of PGE2-
GwasnotinhibitedbyaCB1antagonist,butitwasblockedbyan
IP3 receptor antagonist and a MAPK inhibitor. A second major
eﬀect of endocannabinoids in the hippocampus is the suppres-
sion of long-term potentiation. Yang et al. found that increased
COX-2 expression enhances basal synaptic transmission and
augments long-term potentiation in the mouse hippocampus.
117
This response was blocked by COX-2 inhibitors, and COX-2
gene knockout had an eﬀect opposite that of overexpression.
As in the case of increased COX-2 expression, addition of the
glyceryl ester or ethanolamide of PGD2, PGE2, or PGF2α to
hippocampal slices increased basal synaptic transmission and
long-term potentiation, and these eﬀects were attenuated by IP3
receptorblockadeandMAPKinhibition.Together,theresults of
Sang etal.andYang etal.support theconclusionsofNirodi etal.
and Richie-Janetta et al. that the prostanoid esters and ethanol-
a m i d e sa c ta to n eo rm o r ea sy e tu n k n o w nr e c e p t o r sv i a
IP3-dependent Ca
2+ mobilization and activation of MAPK.
However, it should be noted that the concentrations of ligand
used in the hippocampus studies were quite high (1030 μM),
a n dn od o s e response experiments to determine the potencies of
the various prostanoid esters and amides were reported. Thus, the
sensitivityandspeciﬁcityoftheputativereceptor(s) remainunclear.
A number of additional studies have suggested biological
activities for PG-Gs and PG-EAs. For example, Hu et al. showed
thatPGE2-GinduceshyperalgesiaandmodulatesNF-kBactivity
in carageenan-induced inﬂammation in the rat paw.
70 The
pharmacology of this response was distinct from that of PGE2,
suggesting that it was not mediated by EP receptors, although
hydrolysis of PGE2-G to PGE2 was demonstrated in the paw.
Patsosetal.showed thatAEAinducedcelldeath inanapoptosis-
resistant colon cancer cell line by a mechanism requiring COX-2
activity.
118 They also showed that PGE2-EA and PGD2-EA
induce apoptosis in colorectal cancer cells, whereas PGE2 was
reported to induce proliferation in these cells.
119 Correa et al.
demonstrated that, like AEA, PGE2-EA suppresses the expres-
sion of interleukin 12 (IL-12) and IL-23 in microglial cells.
120
However,theseeﬀectswerepartiallyblocked byanEP2receptor
blocker, so it is possible that the active compound was PGE2
formed after hydrolysis of PGE2-EA and/or following hydrolysis
and oxygenation of AEA. Van Dross et al. demonstrated that
PGD2-EA is cytotoxic to squamous cell carconima cells, but the
ﬁnding that PGD2 has the same eﬀect suggests that this may be
the active compound.
82
3.3. Oxygenation as a Termination of Endocannabinoid
Signaling
A growing number of studies suggest that COX- or LOX-
dependent oxygenation serves as a mechanism to terminate
endocannabinoid signaling by removing the active ligand. As
noted above, available data indicate that PG-EAs, and likely
PG-Gs, do not bind to the CB receptors, so COX-dependent
endocannabinoid oxygenation results in inactivation. The ma-
jority of studies supporting this hypothesis depend on the use of
nonselective,COX-2-selective,orLOXinhibitors.Ifoxygenation
is involved in termination of endocannabinoid signaling, block-
ade of the relevant COX or LOX enzymeswill lead tofacilitation
of signaling by increasing the levels of the endocannabinoids.
However, a potentially confounding aspect of using NSAIDs as
COX inhibitors in studies of endocannabinoid-eicosanoid cross-
talk arises from reports that some of these compounds also
inhibit FAAH.
121 In a rank order of decreasing potency, FAAH
inhibitory activity was reported for suprofen > ibuprofen >
fenoprofen > naproxen > ketoprofen > diclofenac > sulindac.
Isobutyric acid, hydrocinnamic acid, acetylsalicylic acid, and
acetaminophen were inactive. Later work showed ketorolac and
ﬂurbiprofen to be more potent than ibuprofen and revealed stereo-
selectivity for the (R)-isomers of ibuprofen and ketorolac.
122,123
It is notable that the active enantiomer for COX inhibition is (S)
for ibuprofen and ketorolac, thus diﬀerentiating between the
FAAH and COX inhibitory activities. The IC50 values for FAAH
inhibition by (S)-ketorolac and (R,S)-ﬂubiprofen, inthe range of
50μMareclinicallyrelevant,sincesimilarconcentrationsmaybe
reached in the plasma of patients taking these compounds as
anti-inﬂammatory drugs. Holt et al. have proposed that the
combination of COX and FAAH inhibition provides the basis
for an improved anti-inﬂammatory agent, which would not only
block the synthesis of pro-inﬂammatory prostanoids, but also
prolong the anti-inﬂammatory and antinociceptive action of
endocannabinoids.
124 They conducted structureactivity rela-
tionship studies that yielded the 6-methylpyridin-2-yl derivative
of ibuprofen. This compound exhibited substantially higher
FAAH inhibitory potency (IC50 ≈ 8 μM) than ibuprofen
(IC50 ≈ 100 μM), while retaining ibuprofen’s COX inhibitory
activity. The clinical value of this approach remains to be
evaluated as well as the utility of the compounds as probes for
FAAH inhibition. An IC50 value of 50 μM is much higher than
theIC50valuesofmostNSAIDsforinhibitionofCOXactivityin
intact cells.
The antinociceptive activity of NSAIDs has traditionally been
attributed to their inhibition of free acid PG synthesis by COX
enzymes. This mechanism is well supported in the case of pain
signalsarisingatthesiteofperipheralinﬂammation,buthasbeen
questionedwithregardtocentralpaintransmissionatthelevelof
the spinal cord. For example, Ates et al.
125 showed that the
NSAID ﬂurbiprofen is antinociceptive in the formalin-induced
nociception model in the rat. However, intrathecal injection of
PGE2 is also antinociceptive in this model. Thus, blocking PGE2
formation by COX inhibition cannot be the mechanism of the
antinociceptiveaction ofintrathecalﬂurbiprofen. Ates etal.went
ontoshowthatﬂurbiprofen’santinociceptiveactionwasblocked
by a CB1 antagonist but not by adding PGE2, suggesting that it
was endocannabinoid-mediated. Support for this conclusion
comes from the work of G€ uhring et al.,
126 who demonstrated
that CB1 receptor knockout or a CB1 antagonist, but not PGE2,
blocked the antinociceptive action of the NSAID indomethacin
in the formalin pain model. Seidel et al. showed that tetrahy-
drocannabinol and ﬂurbiprofen inhibit capsaicin-induced calci-
tonin gene related peptide release from the spinal cord, another
model of central nociceptive nerve transmission.
127 As in the
reportsofAtesetal.andG€ uhringetal.,thiseﬀectwasblockedby
a CB1 antagonist but not by PGE2. In all of these cases, the
investigators concluded that ﬂurbiprofen increased endocanna-
biniod tone by blocking COX-mediated oxygenation of AA,
thereby increasing the pool of AA available for AEA synthesis.
They argued that this eﬀect, combined with inhibition of FAAH
(inthecaseofﬂurbiprofen),accountedfortheNSAID-mediated
increased endocannabinoid tone. However, they did not con-
sider the possibility that the NSAIDs acted by inhibiting the
direct COX-dependent oxygenation of AEA or 2-AG, which is5916 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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not excluded by their data. In contrast, Bishay et al. showed that
(R)-ﬂubiprofen reduces pain transmission in a sciatic nerve
injury model by reducing glutamate release in the dorsal horn
ofthespinalcord. Thiseﬀect wasmediated byincreasedlevelsof
endocannabinoids. Since (R)-ﬂurbiprofen is the inactive isomer
withregardtoCOXinhibition,Bishayetal.arguedthatincreased
endocannabinoid levels in this model resulted from (R)-ﬂurbi-
profen-mediated FAAH inhibition and a reduction in the ex-
pression of NAPE-PLD.
128
Despite these potential points of confusion, a series of addi-
tionalstudiesarguestronglythatCOX-2playsaroleinregulation
ofsignalingbyendocannabinoids.Kimetal.showed thatCOX-2
inhibitorsprolongendocannabinoid-mediatedDSIinhippocam-
pal slices.
129 FAAH inhibitors did not have the same eﬀect, and
theCOXinhibitorsused,nimesulideandmeloxicam,donothave
FAAHinhibitoryactivity.Thus,Kimetal.attributedtheeﬀectsof
the COX-2 inhibitors to blockade of 2-AG oxygenation. Further
evidence that COX-2 plays a role in modulating endocannabi-
noid signaling in the hippocampus comes from Straiker et al.,
who characterized murine hippocampal neurons with regard to
their temporalresponse to activation of endocannabinoidsignal-
ing by direct depolarization.
94 They found two populations of
neuronsthatrespondedtoendocannabinoidactivationwithDSI.
One of these populations exhibited rapid recovery from this
suppression, while the other population recovered much more
slowly. The rapidly recovering cells were sensitive to COX-2
inhibition, which caused a prolongation of the endocannabinoid
eﬀect. In a subsequent study, Straiker et al. showed that over-
expressionofCOX-2inculturedexcitatoryautaptichippocampal
neuronsresultsinamorerapidrecoveryfromDSE.
130Together,
these ﬁndings suggest that COX-2-dependent metabolism of
endocannabinoids is responsible for a termination of endo-
cannabinoid signaling that results in rapid desuppression in
these cells.
As noted above, in addition to mediating DSI or DSE, endo-
cannabinoids also act to inhibit long-term potentiation in the
hippocampus. Slanina et al. showed that COX-2-selective in-
hibitors, but not COX-1-selective inhibitors, blocked the devel-
opmentof long-term potentiation inrathippocampalslices inan
endocannabinoid-dependentmanner.
131Endocannabinoids also
exert a tonic suppression of synaptic responses evoked upon
stimulationofSchaﬀercollateralsinthehippocampus.
132COX-2
inhibitorsincreasedthesuppressionofexcitatory transmissionin
these cells. The investigators concluded that, in both of these
models, COX-2 inhibitors may block oxygenation of endocan-
nabinoids, resulting in increased endocannabinoid tone and
signaling.
The studies described above all relied on pharmacology to
dissect the role of COX-2 in endocannabinoid regulation. How-
ever, a number of investigators have actually measured endo-
cannabinoidlevelsandshownthatCOX-2inhibitionresultsinan
increase in those levels. Wang et al. reported that AEA and 2-AG
levels are increased in COX-2 knockout mice.
133 Telleria-Diaz
used a model of inﬂammation in the rat knee joint that is
characterized by spinal neuron hyperexcitability.
134 In this mod-
el, COX-2 inhibitors reversed hyperexcitability after inﬂamma-
tion was established, and this eﬀect was accompanied by an
increase in 2-AG levels. The ﬁnding that the eﬀects of COX-2
inhibitors were partially blocked by a CB1 antagonist led Tell-
eria-Diazetal.toconcludethatonemechanismbywhichCOX-2
inhibitors suppress hyperexcitability is through facilitation of
endocannabinoidsignaling. Jhaveri etal. reportedthatthe COX-2
inhibitor nimesulide increased levels of AEA in the paws of
rats treated with carageenan to induce inﬂammation.
135 This result
suggests that COX-2 inhibition prevents oxygenation of AEA,
leading to higher levels. However, the discovery that nimesu-
lide also leads to increased levels of palmitoylethanolamide,
whichisnotaCOX-2substrate, callsthisinterpretation ofthe
data into question. Furthermore, although Staniaszek et al.
found that CB1 receptor blockade inhibited the antinocicep-
tive action of intrathecal nimesulide in a model of mechanical
allodynia, the NSAID treatment had no eﬀect on 2-AG levels
and actually decreased levels of AEA in the spinal cords of
treated animals.
136
Glaser et al. reported a novel, albeit indirect, approach to
monitor COX-2-mediated endocannabinoid metabolism. Their
method was based on the knowledge that, following AEA or
2-AG hydrolysis, the free AA is rapidly incorporated into cellular
membrane lipids. Thus, mice injected intravenously with
[
3H]AEA carrying the label in the AA moiety will exhibit the
incorporatedlabelupontissueautoradiographywithin15min.In
contrast, the products of COX-2-dependent oxygenation are not
incorporated into lipids, so the presence of this pathway would
lead to a reduction in the amount of radiolabel detected by
autoradiography. Glaser et al. pretreated mice with the COX-2-
selective inhibitor nimesulide, or vehicle, prior to an intravenous
injection of [
3H]AEA. Subsequent autoradiography of brain
tissue from the mice revealed increased label in the nimesulide-
treated mice as compared to the control. The investigators
concluded that the increase in label in the presence of the
COX-2-selective inhibitor represented the amount of AEA that
is oxygenated by COX-2 as opposed to inactivated by FAAH-
mediated hydrolysis.
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Most of the data discussed above are consistent with the
hypothesis that COX-2 modulates endocannabinoid tone by
converting 2-AG and AEA into oxygenated derivatives that are
not active at the cannabinoid receptors. However, it is important
that we do not develop tunnel vision in interpreting these data.
Clearly, other mechanisms may explain the ability of COX-2
inhibitors to increase apparent endocannabinoid signaling. As
noted above, some investigators have proposed that free AA not
used for PG synthesis is diverted to endocannabinoid formation
in NSAID-treated animals. It is also possible that free acid
prostanoids produced by COX-2 suppress endocannabinoid
release or responses. Finally, in the case of parecoxib and
valdecoxib,adirectinteractionofthedrugwiththeCB1receptor
hasbeenreported.
138Clearly,furtherworkisrequiredtodevelop
a full understanding of the role of COX-2-dependent oxygena-
tion on the modulation of endocannabinoid signaling.
3.4. Substrate-Selective COX-2 Inhibition
NSAIDs are among the oldest, most widely used, and thor-
oughlystudieddrugs inthemodernpharmacopeia. Assuch, they
have proven extremely useful in determining the role of COX
enzymes in physiology and pathophysiology. The newer COX-2-
selective coxibs have served a similar function for the elucidation of
the speciﬁc role of the COX-2 isoform in conditions such as
inﬂammation and cancer. However, when used at concentrations
thatblockAAoxygenationbyCOX-2,bothNSAIDsandcoxibsalso
blockendocannabinoidoxygenation.Consequently,theyhavebeen
of limited value for the selective study of COX-2-dependent
endocannabinoid metabolism in vivo.
Recently, Prusakiewicz et al. reported that weak, compe-
titive inhibitors of AA oxygenation by COX-2, such as5917 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
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ibuprofenandmefenamicacid,arepotent,time-dependentinhibitors
of 2-AG oxygenation.
139 The diﬀerences in potency for the two
activities are reﬂected in the Ki values for inhibition of AA versus
2-AG oxygenation. The reported values were 60 μM versus 1.2 μM
for ibuprofen and 10 μM versus 4 nM for mefenamic acid,
respectively. The diﬀerences in kinetic behavior and binding con-
stants observed for the two substrates strongly suggest distinct
inhibitory mechanisms. This led Prusakiewicz et al. to propose that
the two subunits of the COX-2 homodimer act diﬀerently with
regard to inhibitor interactions (Figure 13). In the case of inhibitors
such as ibuprofen and mefenamic acid, the ﬁrst molecule binds to
one subunit of COX-2 with high aﬃnity. This induces a conforma-
tional change in the second subunit that eﬀectively blocks oxygena-
tionof2-AG,butnotAA,atthatsubunit.ToinhibitAAoxygenation,
a second molecule of inhibitor must bind in the remaining subunit’s
activesite,butthisinteraction occurswith lower aﬃnity. Thus, 2-AG
oxygenation is blocked by high-aﬃnity inhibitor binding to the ﬁrst
subunit in a noncompetitive fashion, while AA oxygenation is
blockedbyloweraﬃnity,competitivebindingtothesecondsubunit.
Substrate-selective inhibition was not observed for potent,
time-dependentCOXinhibitorssuchasindomethacin.Forthese
compounds, Prusakiewicz et al. proposed that tight binding of a
singlemoleculeofinhibitorinonesubunitissuﬃcienttoinducea
conformational change that blocks oxygenation of both AA and
2-AG. The mechanism proposed for substrate-selective inhibi-
tion is consistent with reports from the Smith laboratory. They
haveshownthatbindingofafattyacidmoleculetoonesubunitof
COX induces a conformational change that alters the capacity of
the second subunittocatalyzetheoxygenation reaction.
140They
have also shown that binding of a molecule of celecoxib to one
subunit of COX-2 induces a conformational change that inhibits
binding of aspirin in the second subunit.
141 Thus, growing evid-
ence supports the hypothesis that the two subunits of COX
homodimers act as functional heterodimers.
The discovery of substrate-selective inhibition provides a
mechanism by which 2-AG oxygenation may be pharmacologi-
cally distinguished from AA oxygenation in vivo. However, further
work will be required to reﬁne the conditions needed to achieve
this goal.
4. FUTURE CHALLENGES
The fact that the endocannabinoids AEA and 2-AG are meta-
bolites of AA ensures that there must be cross-talk between the
endocannabinoid and eicosanoid signaling systems. However,
the complexity of the possible interrelationships was not fully
appreciated until the ﬁrst reports that some LOX enzymes and
COX-2 can oxygenate both AEA and 2-AG as well as AA.
Evidence is mounting that these biochemical conversions are
more than a test tube curiosity. Both LOX- and COX-2-derived
endocannabinoid metabolites have biological activities distinct
from those of their free acid counterparts, and considerable data
support the hypothesis that COX-2-dependent oxygenation mod-
ulates endocannabinoid tone. Despite these advances, questions
remain regarding the importance of these pathways in health and
disease. Challenges for future research include the following:
(1) Quantifying endocannabinoid oxygenation in vivo. As
noted above, rapid hydrolysis of endocannabinoid-de-
rived oxygenated products yields free acid eicosanoids
that are indistinguishable from those produced by direct
metabolism of AA. Thus, despite the availability of
excellent mass-spectrometry-based assays for oxygenated
endocannabinoids,
142 determination of the actual levels
of these compounds produced in vivo remains elusive. It
should benoted that a precedent exists for the generation
of short-lived biologically active eicosanoids. Both PGI2
and TXA2 are chemically unstable and undergo rapid
hydrolysis in vivo. However, in the case of these two
compounds, a distinctive decomposition product allows
estimation of the amount of eicosanoid originally pro-
duced. This is not the case for enzymatic hydrolysis of
endocannabinoid-derived oxygenation products. A possi-
ble solution to this dilemma is to identify the hydrolytic
enzymes so that chemical or genetic inhibition can be
used to block the degradation pathway. In the absence of
hydrolysis, the full quantity of oxygenated endocannabi-
noids may then be assessed.
(2) Asnotedabove,considerableevidencesupportsthehypo-
thesis that oxygenated endocannabinoids exert biological
activities through distinct receptors. However, with the
exception of the prostamides (section 3.2.2), no speciﬁc
receptors for these ligands have been characterized.
Clearly, receptor identiﬁcation is a major goalinclarifying
the role that these pathways play in vivo. The existence of
speciﬁc receptors would lend support to the hypothesis
that endocannabinoid oxygenation has a deﬁned physiolo-
gical function, and receptor blockade or knockout can be
used to interrogate that function under various physiolo-
gical or pathological conditions.
(3) Evidence is mounting to support the hypothesis that
oxygenation serves as a mechanism to modulate endo-
cannabinoid tone. This scenario is particularly appealing
in the central nervous system, where the eﬀects of NSAIDs
appear to be endocannabinoid-dependent, and under
conditions of inﬂa m m a t i o nt h a tw o u l dl e a dt oi n c r e a s e d
expression of COX-2. Indeed, reduction in levels of anti-
inﬂammatory endocannabinoids may be one mechanism by
which COX-2exertsitspro-inﬂammatoryeﬀects.Therecent
discovery of substrate-selective inhibition may provide an
approach for determining the role of COX-2-dependent
oxygenation in modulation of endocannabinoid tone.
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Figure 13. Mechanism of substrate-selective inhibition of endocanna-
binoid oxygenation by rapid, reversible inhibitors of COX-2. Inhibitor
binding in one subunit of the homodimer induces a conformational
change in the second subunit, which blocks 2-AG and AEA oxygenation
butnotAAoxygenation.Anothermolecule ofinhibitormustbindinthe
second subunit to inhibit AA oxygenation. Reprinted from ref 134.
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ABBREVIATIONS
CB1 cannabinoid receptor 1
CB2 cannabinoid receptor 2
AEA arachidonoylethanolamide
2-AG 2-arachidonoylglycerol
AA arachidonic acid
PG prostaglandin
cPLA2 cytosolic phospholipase A2
COX cyclooxygenase
PGI2 prostacyclin
TX thromboxane
LOX lipoxygenase
HPETE hydroperoxyeicosatetraenoic acid
HETE hydroxyeicosatetraenoic acid
LT leukotriene
EET epoxyeicosatrienoic acid
PLC phospholipase C
PIP2 phosphatidylinositol 4,5-bisphosphate
DAG diacylglycerol
PC phosphatidylcholine
PLD phospholipase D
MAG monoacylglycerol
ABHD α,β-hydrolase domain
FAAH fatty acid amide hydrolase
CES carboxylesterase
NAPE N-arachidonoylphosphatidylethanolamine
PE phosphatidylethanolamine
NAT N-acyltransferase
NAPE-PLD
N-acylphosphatidylethanolamine-hydrolyzing PLD
HETE-EA
hydroxyeicosatetraenoic acid ethanolamide
HETE-Ghydroxyeicosatetraenoic acid glyceryl ester
NAGly N-arachidonoylglycine
NAla N-arachidonoylalanine
NAGABA
N-arachidonoyl-γ-aminobutyric acid
NADA N-arachidonoyldopamine
arvanil N-arachidonoylvanillylamide
OMDA O-(3-methyl)-N-arachidonoyldopamine
N-AT N-arachidonoyltaurine
DHEA docosahexaenoylethanolamide
PMN polymorphonuclear leukocyte
15-HEDPEA
(15-hydroxy-16(17)-epoxydocosapentaenoyl)ethanolamide
NSAID nonsteroidal anti-inﬂammatory drug
coxib COX-2-selective inhibitor
PG-EA prostaglandin ethanolamide
HHT 12-hydroxyheptadecatrienoic acid
EET-EA epoxyeicosatrienoic acid ethanolamide
RPM resident peritoneal macrophage
LPS lipopolysaccharide
IFN-γ interferon-γ
PG-G prostaglandin glyceryl ester5919 dx.doi.org/10.1021/cr2002799 |Chem. Rev. 2011, 111, 5899–5921
Chemical Reviews REVIEW
DSI depolarization-induced suppression of inhibition
DSE depolarization-induced suppression of excitation
IP3 inositol trisphosphate
PKC protein kinase C
MAPK mitogen-activated protein kinase
ERK extracellular signal regulated kinase
mIPSC miniature inhibitory postsynaptic current
PPAR peroxisome proliferator-activated receptor
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